Kenvue (NYSE:KVUE) PT Raised to $21.00

Kenvue (NYSE:KVUE) had its target price lifted by stock analysts at Piper Sandler from $20.00 to $21.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Piper Sandler’s price target would indicate a potential downside of 8.77% from the company’s current price.

Several other research firms also recently commented on KVUE. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. JPMorgan Chase & Co. increased their price objective on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. UBS Group lifted their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft increased their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Citigroup reduced their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $21.56.

Kenvue Trading Up 0.5 %

Shares of Kenvue stock opened at $23.02 on Monday. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $23.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The company has a market capitalization of $44.08 billion, a P/E ratio of 29.51, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a fifty day moving average of $20.92 and a 200 day moving average of $19.96.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter last year, the business posted $0.32 earnings per share. The firm’s revenue was down .3% on a year-over-year basis. On average, sell-side analysts anticipate that Kenvue will post 1.08 earnings per share for the current fiscal year.

Institutional Trading of Kenvue

Institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after acquiring an additional 25,238,112 shares during the period. Vanguard Group Inc. raised its position in Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after purchasing an additional 17,908,497 shares during the period. Van ECK Associates Corp lifted its stake in Kenvue by 110.9% in the second quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock worth $372,880,000 after purchasing an additional 10,783,258 shares during the last quarter. Clearbridge Investments LLC boosted its position in shares of Kenvue by 16,051.1% during the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock valued at $210,600,000 after buying an additional 9,752,836 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Kenvue by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock valued at $789,813,000 after buying an additional 7,546,362 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.